According to Lilly, the Medicines and Medical Products Regulatory Authority (MHRA) in the UK has granted marketing authorization for its drug, donanemab, for Alzheimer's disease. Donanemab (trade name: Kisunla) is a medication used for intravenous infusion, administered once every four weeks, approved in the UK for the treatment of eligible adult patients with mild cognitive impairment and mild Alzheimer's disease (AD). Previously, donanemab had obtained marketing authorization in the United States, United Arab Emirates, Japan, and Qatar.